血栓弹力图（TEG）在冠状动脉介入治疗患者抗血小板治疗监测中的应用
|
摘要
目的
通过对检查血栓弹力图(TEG)的冠状动脉介入治疗患者临床病历的回顾性调查研究,对不同临床分型的冠心病患者凝血特点进行分析,并对PCI术后可能发生抗血小板药物反应低下及近期缺血事件的相关危险因素进行分析总结,探讨TEG在冠状动脉介入治疗患者抗血小板治疗监测中的应用价值及实用性。
方法
入选2010年10月1日至2011年1月31日间在天津胸科医院临床资料相对完整、行PCI治疗并应用TEG监测抗血小板疗效的冠心病患者150例,据冠心病临床分型标准分为急性心肌梗死(AMI)组、不稳定型心绞痛(UAP)组、稳定型心绞痛(AP)组,比较分析各组间TEG、凝血全项指标的差异；据PCI术后TEG检测的血小板聚集抑制率不同,分为抗血小板约物反应低下组和抗血小板药物反应正常组,比较分析可能发生抗血小板药物反应低下的相关危险因素；据出院三月内有无缺血事件分为有事件组和无事件组,比较分析可能发生近期缺血事件的相关危险因素。
结果
1、入选的150例患者平均年龄61.35±10.41岁(44-84岁),其中AMI组51例,占总数的34.00%；UAP组86例,占总数的57.33%；AP组13例,占总数的8.67%。(1)AMI组、UAP组与AP组比较,TEG的常规参数：R值、K值明显缩短,MA值、Angle明显增大,TEG高凝图形出现的比例明显增高,P均<0.01,差异有统计学意义；(2)D-二聚体在AMI组、UAP组以及AP组三组间有差异,P均<0.05,差异有统计学意义；(3)在AMI组活化部分凝血活酶时间(APTT)、国际标准化比值(INR)明显减低,与UAP组、AP组比较,P均<0.05,差异有统计学意义。
2、抗血小板药物反应低下组(包括氯吡格雷反应低下和阿司匹林反应低下)中糖尿病患者、吸烟者所占的比例较抗血小板药物反应正常组明显增高,P均<0.05,差异有统计学意义。Logistic多元回归分析显示糖尿病、吸烟为抗血小板药物反应低下的独立危险因素。
3、与无事件组比较,有事件组Fgb增高,TEG检测ADP诱导的血小板聚集抑制率明显减低,P均<0.05,差异有统计学意义。Logistic多元回归分析显示Fgb、氯吡格雷反应低下是近期缺血事件的独立危险因素。
结论：
1、AMI组、UAP组与AP组相比,TEG高凝图形所占比例明显增高,TEG常规参数R值、K值缩短,MA值、Angle增大,呈现相对的高凝状态,以AMI组为著,对于AMI和UAP患者,需给予充分的抗凝治疗。
2、糖尿病患者易发生抗血小板药物反应低下,行PCI且合并糖尿病的冠心病患者应积极控制血糖,及早加用三联抗血小板治疗。
3、吸烟可能影响血小板对氯吡格雷的反应性。
4、近期缺血事件可能与氯吡格雷反应低下、Fgb增高有关,据TEG对血小板聚集抑制率的监测指导抗血小板用药,并积极降纤治疗,近期缺血事件可能减少。
5、TEG对PCI患者抗血小板的治疗监测有一定应用价值。
Objective
According to the retrospective investigation into clinical records of patients who accepted the percutaneous coronary intervention(PCI) undergoning the thrombelastogram examination,We analyzed the feature of clotting in different clinical types of CHD patients,the relevant factors of low reaction to antiplatelet drugs and recent ischemia events in patients who accepted PCI and discussed the significance and practical applicability of TEG to antiplatelet therapy monitoring in the patients who accepted PCI.
Methods
150 CHD patients with relatively complete clinical data were adopted who had accepted PCI and monitored antiplatelet therapy with TEG in Tianjin Chest Hospital from Oct 1st,2010 to Jan 31st,2011.The patients were divided into Acute Myocardial Infarction (AMI) group,Unstable Angina Pectoris (UAP) group and Angina Pectoris (AP) group according to CHD clinical classification.To analysis the differences in TEG & coagulation test among the groups.All patients were divided into low reaction group and normal group according to the platelet agglutination inhibition rate examed by TEG after PCI.To analyze the related factors that may affect the reaction to antiplatelet drugs.We divided all the patients into incident group and non-incident group according to whether ischemia events happened in three months after hospitalization.To analyze the related factors that may have influence on recent ischemia events.
Results
1. The average age of the 150 patients were 61.35±10.41 (44-84 years old). There were 51 patients (34.00%) in AMI group,86 patients (57.33%) in UAP group,13 patients (8.67%) in AP group.(1)Compared with AMI group,the R and K value cut short (P<0.05),and both MA and Angle value amplified (P<0.05),the frequency of high coagulate images of TEG obviously get much higher(P<0.01) in UAP group and AP group.(2)There were significance differents in D-dimer among AMI group, UAP group and AP group.(3)Activated Partial Thromboplastin Time (APTT) and International Normalized Radio (INR) were reduced obviously in AMI group which compared with UAP group and AP group (P<0.05).
2. Proportion of diabetics and smokers were obvious higher in low reaction to antiplatelet drugs group than in normal group (P<0.05).Logistic multiple regression analysis showed that diabetic and smoke were independent factors of low reaction to antiplatelet drugs.
3. Fgb value got much higher and the platelet agglutination inhibition rate which were induced by ADP in event group was obviously lower than in non-event group (P<0.05).Logistic multiple regression analysis showed that Fgb and low reaction to clopidogrel were independent factors of recent ischemia events.
Conclusions
1. AMI and UAP-especially AMI-were relative more hypercoaguloability image and R, K get shorter and MA,Angle get much more in TEG when that compared with AP.Sufficient anticoagulation therapy must be given to the patients who have AMI and UAP.
2. Low reaction of antiplatelet drugs tends to occur in diabetic patients.The CHD patients with diabetes should control their blood sugar and add trigeminy resist platelet treatment much earlier when they received PCI.
3. Smoking probably has influence on the reactivity of platelet to clopidogrel.
4. Recent ischemia events were probably related to low reaction to clopidogrel and Fgb.Using antiplatelet drugs according to monitoring the platelet agglutination inhibition rate and decreasing the fibrinogen concentration may reduce the recent ischemia events.
5. TEG is helpful in monitoring antiplatelet therapy in the patients who accepted PCI.
通过对检查血栓弹力图(TEG)的冠状动脉介入治疗患者临床病历的回顾性调查研究,对不同临床分型的冠心病患者凝血特点进行分析,并对PCI术后可能发生抗血小板药物反应低下及近期缺血事件的相关危险因素进行分析总结,探讨TEG在冠状动脉介入治疗患者抗血小板治疗监测中的应用价值及实用性。
方法
入选2010年10月1日至2011年1月31日间在天津胸科医院临床资料相对完整、行PCI治疗并应用TEG监测抗血小板疗效的冠心病患者150例,据冠心病临床分型标准分为急性心肌梗死(AMI)组、不稳定型心绞痛(UAP)组、稳定型心绞痛(AP)组,比较分析各组间TEG、凝血全项指标的差异；据PCI术后TEG检测的血小板聚集抑制率不同,分为抗血小板约物反应低下组和抗血小板药物反应正常组,比较分析可能发生抗血小板药物反应低下的相关危险因素；据出院三月内有无缺血事件分为有事件组和无事件组,比较分析可能发生近期缺血事件的相关危险因素。
结果
1、入选的150例患者平均年龄61.35±10.41岁(44-84岁),其中AMI组51例,占总数的34.00%；UAP组86例,占总数的57.33%；AP组13例,占总数的8.67%。(1)AMI组、UAP组与AP组比较,TEG的常规参数：R值、K值明显缩短,MA值、Angle明显增大,TEG高凝图形出现的比例明显增高,P均<0.01,差异有统计学意义；(2)D-二聚体在AMI组、UAP组以及AP组三组间有差异,P均<0.05,差异有统计学意义；(3)在AMI组活化部分凝血活酶时间(APTT)、国际标准化比值(INR)明显减低,与UAP组、AP组比较,P均<0.05,差异有统计学意义。
2、抗血小板药物反应低下组(包括氯吡格雷反应低下和阿司匹林反应低下)中糖尿病患者、吸烟者所占的比例较抗血小板药物反应正常组明显增高,P均<0.05,差异有统计学意义。Logistic多元回归分析显示糖尿病、吸烟为抗血小板药物反应低下的独立危险因素。
3、与无事件组比较,有事件组Fgb增高,TEG检测ADP诱导的血小板聚集抑制率明显减低,P均<0.05,差异有统计学意义。Logistic多元回归分析显示Fgb、氯吡格雷反应低下是近期缺血事件的独立危险因素。
结论：
1、AMI组、UAP组与AP组相比,TEG高凝图形所占比例明显增高,TEG常规参数R值、K值缩短,MA值、Angle增大,呈现相对的高凝状态,以AMI组为著,对于AMI和UAP患者,需给予充分的抗凝治疗。
2、糖尿病患者易发生抗血小板药物反应低下,行PCI且合并糖尿病的冠心病患者应积极控制血糖,及早加用三联抗血小板治疗。
3、吸烟可能影响血小板对氯吡格雷的反应性。
4、近期缺血事件可能与氯吡格雷反应低下、Fgb增高有关,据TEG对血小板聚集抑制率的监测指导抗血小板用药,并积极降纤治疗,近期缺血事件可能减少。
5、TEG对PCI患者抗血小板的治疗监测有一定应用价值。
Objective
According to the retrospective investigation into clinical records of patients who accepted the percutaneous coronary intervention(PCI) undergoning the thrombelastogram examination,We analyzed the feature of clotting in different clinical types of CHD patients,the relevant factors of low reaction to antiplatelet drugs and recent ischemia events in patients who accepted PCI and discussed the significance and practical applicability of TEG to antiplatelet therapy monitoring in the patients who accepted PCI.
Methods
150 CHD patients with relatively complete clinical data were adopted who had accepted PCI and monitored antiplatelet therapy with TEG in Tianjin Chest Hospital from Oct 1st,2010 to Jan 31st,2011.The patients were divided into Acute Myocardial Infarction (AMI) group,Unstable Angina Pectoris (UAP) group and Angina Pectoris (AP) group according to CHD clinical classification.To analysis the differences in TEG & coagulation test among the groups.All patients were divided into low reaction group and normal group according to the platelet agglutination inhibition rate examed by TEG after PCI.To analyze the related factors that may affect the reaction to antiplatelet drugs.We divided all the patients into incident group and non-incident group according to whether ischemia events happened in three months after hospitalization.To analyze the related factors that may have influence on recent ischemia events.
Results
1. The average age of the 150 patients were 61.35±10.41 (44-84 years old). There were 51 patients (34.00%) in AMI group,86 patients (57.33%) in UAP group,13 patients (8.67%) in AP group.(1)Compared with AMI group,the R and K value cut short (P<0.05),and both MA and Angle value amplified (P<0.05),the frequency of high coagulate images of TEG obviously get much higher(P<0.01) in UAP group and AP group.(2)There were significance differents in D-dimer among AMI group, UAP group and AP group.(3)Activated Partial Thromboplastin Time (APTT) and International Normalized Radio (INR) were reduced obviously in AMI group which compared with UAP group and AP group (P<0.05).
2. Proportion of diabetics and smokers were obvious higher in low reaction to antiplatelet drugs group than in normal group (P<0.05).Logistic multiple regression analysis showed that diabetic and smoke were independent factors of low reaction to antiplatelet drugs.
3. Fgb value got much higher and the platelet agglutination inhibition rate which were induced by ADP in event group was obviously lower than in non-event group (P<0.05).Logistic multiple regression analysis showed that Fgb and low reaction to clopidogrel were independent factors of recent ischemia events.
Conclusions
1. AMI and UAP-especially AMI-were relative more hypercoaguloability image and R, K get shorter and MA,Angle get much more in TEG when that compared with AP.Sufficient anticoagulation therapy must be given to the patients who have AMI and UAP.
2. Low reaction of antiplatelet drugs tends to occur in diabetic patients.The CHD patients with diabetes should control their blood sugar and add trigeminy resist platelet treatment much earlier when they received PCI.
3. Smoking probably has influence on the reactivity of platelet to clopidogrel.
4. Recent ischemia events were probably related to low reaction to clopidogrel and Fgb.Using antiplatelet drugs according to monitoring the platelet agglutination inhibition rate and decreasing the fibrinogen concentration may reduce the recent ischemia events.
5. TEG is helpful in monitoring antiplatelet therapy in the patients who accepted PCI.
引文
[1]中国心脏研究协作组.14962例AMI患者临床特征-中国心脏研究专题报告之五[J].高血压杂志,1997,5：91.
[2]Bakhtiari K, C.M. Meijers J, de Jonge E, etc. Prospective validation of the International Society of Thrombosis and Haemostasis Scoring system for disseminated intravascular coagulation [J]. Crit Care Med,2004,32:2416-2421.
[3]Hartert H. Thrombelastography, a method for physical analysis of blood coagulation [J]. Z Gesamte Exp Med,1951,117(2):189-203.
[4]Craft RM, Chavez JJ, Snider CC, et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients [J]. J Lab Clin Med,2005 Jun,145(6):309-315.
[5]Miller BE, Tosonc SR, Guzzctta NA, et al. Fibrinogen in children undergoing cardiac surgery:is it effective? [J] Anesth Analg,2004 Nov,99(5):1341-1346.
[6]Salooja N, Perry DJ. Thrombelastography [J]. Blood Coagul Fibrinolysis,2001 Jul, 12(5):327-337.
[7]Wheeler AP, Bernard GR. Treating patients with severe sepsis [J]. N Engl J,Med, 1999,340:207-214.
[8]叶任高,陆再英.内科学[M].第6版.北京：人民卫生出版社,2004,
[9]周北凡,吴锡桂,主编.心血管病学流行病学调查手册[M].北京：北京医科大学中国协和医科大学联合出版社,1997,69-75.
[10]Harlan M, Krumholz MD, Jeffrey L. Anderson MD, et al. ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction [J]. Circulation,2008 Nov,118(24):2596-2648.
[11]Jeffrey L. Anderson, MD, Cynthia D. Adams, RN, Elliott M. Antman, MD, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [J]. Circulation,2011 Mar,123:e426-e579.
[12]Theodore D, Fraker, MD, Stephan, MD, et al.2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina[J]. Circulation,2007 Nov,116(23):2762-2772.
[13]中国高血压防治指南修订委员会.2004年中国高血压防治指南[J].中华心血管病杂志,2004,32(12)：1060-1064.
[14]叶任高,陆再英.内科学[M].第6版.北京：人民卫生出版社,2004,787-814.
[15]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-413.
[16]Frederick G. Kushner MD, Mary Hand MSPH. Sidney C. Smith Jr MD,et al. 2009 Focused Updates:ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention[J]. Circulation,2009 Dec,120(22):2271-2306
[17]Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation [J]. J Am Coll Cardiol,2005, 46(9):1705-1709.
[18]Pieper CF, Rao KM, Currie MS, et al. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons [J]. Gerontol A Biol Sci Med Sci,2000 Nov,55(11):M649-657.
[19]李晓春,刘东岳.D-二聚体测定在心血管疾病中的临床应用价值[J].国外医学.心血管疾病分册,1997,24(5)：26.
[20]张广森,王鸿利.血栓形成机制,见：李家增,贺石林,王鸿利,等主编.血栓病学[M].北京科学出版社,1998：13-14.
[21]胡豫等.陈旧性心肌梗塞患者凝血纤溶状态的研究[J].同济医科大学学报,1998,27(4)：277-279.
[22]张红雨,宋善俊,涂源淑.冠心病患者血浆纤维蛋白肽A及有关参数的研究[J].临床心血管杂志,1999,15(5)：197-199.
[23]Schlant RC, Forman S, Stajnler J, et al. The natural history of coronary heart disease:prognostic factors after recovery from myocardial infarction in 2789 men. The 5 year findings of the coronary drug project [J].Circulation,1982,66:411-414.
[24]Barron HV, Cannon CP, MurPhy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction:a thrombolysis in myocardial infarction 10 substudy [J].Circulation,2000,102:2329-2334.
[25]Gurm HS, Bhatt DL, Lincoff AM, et al. Impact of preprocedural white. Blood cell count on long term mortality after percutaneous coronary intervention:insights from the EPIC, EPILOG, and EPISTENT trials[J]. Heart,2003,89(10):1200-1204.
[26]Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 investigators [J]. Am J Cardiol,2001,87:636-639.
[27]Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease [J]. Ann Intern Med,1951 Jun, 34(6):1421-1431.
[28]Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I Epidemiologic Follow-up Study,1971-1992 [J]. National Health and Nutrition Examination Survey [J]. JAMA,2000 May 10,283(18):2404-2410.
[29]Alderman MH. Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients[J]. Hypertension,1999 Jul,34(1):144-150.
[30]Nieto FJ, Iribarren C, Gross MD, et al. Uric acid and serum antioxidant capacity:a reaction to atherosclerosis[J]? Atherosclerosis,2000 Jan,148(1):131-139.
[31]Cianflone D, Ciccirillo F, Buffon A, et al. Comparison of coronary angiograpbic narrowing in stable angina pectoris, unstable angina pectoris and in acute myocardial infarction [J]. Am J cordial,1995 Aug 1,76(4):215-219.
[32]Bogaty P, Brecker SJ, White SE, et al. Comparison of coronary angiographic findings in acute and chronic first presentation of ischemic heart disease[J]. Circulation,1993 Jun,87(6):1938-1946.
[33]郑鹏翔,华尔铨,张书富等.稳定性心绞痛,不稳定型心绞痛,急性心肌梗死的冠脉造影特点[J].中国医药指南,2005,3(5)：90-492.
[34]De Feyter PJ, Ozaki Y, Baptista J, et al. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound[J]. Circulation,1995 Sep 15,92(6):1408-1413.
[35]戴军,高润霖,陈纪林等.35岁以下与45岁以上心肌梗塞患者临床特征比较[J].中华内科杂志,1999,38(2)：104-106.
[36]Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly[J]. N Engl J Med,1997 May 1,36(18):1276-1282.
[37]Krasopoulos G, Brister SJ, Beattie WS,et al. Aspirin "resistance" and risk of cardiovascular morbidity:systematic review and meta-analysis[J]. BMJ,2008 Jan 26, 336(7637):195-198.
[38]Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance:position paper of the Working Group on Aspirin Resistance [J]. J Thromb Haemost,2005 Jun, 3(6):1309-1311.
[39]Patrono C. Aspirin resistance:definition, mechanisms and clinical read-outs[J]. J Thromb Haemost,2003 Aug,1(8):1710-1713.
[40]Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting:results of the PREPARE POST-STENTING Study[J]. J Am Coll Cardiol,2005 Nov 15,6(10):1820-1826.
[41]Sztriha L, Sas K, Vecsei L. Aspirin resistance in stroke:2004[J]. J neurol sci,2005 Mar 15,229-230:163-169.
[42]Wiviott SD, Antman EM. Clopidogrel resistance:a new chapter in a fast-moving story [J].Circulation,2004 Jun 29,109(25):3064-3067.
[43]Patrono C, Baigent C, Hirsh J. Roth G. Antiplatelet drugs:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [J]. Chest,2008 Jun,33(6 Suppl):199S-233S.
[44]Hennekens CH, Schror K, Weisman S, et al. Terms and conditions:semantic complexity and aspirin resistance [J]. Circulation,2004 Sep 21,10(12):1706-1708.
[45]Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance [J]. J Am Coll Cardiol,2006 Jan 3,47(1):27-33.
[46]FitzGerald GA. Parsing an enigma:the pharmacodynamics of aspirin resistance[J]. Lancet,2003 Feb 15,361(9357):542-544.
[47]Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital[J]. Am J Cardiol,2006 Sep 1,98(5):577-579.
[48]徐晓微,杜凤和.根据血栓弹力图结果指导急性冠脉综合征患者抗血小板药 物的使用[J].中国医师进修杂志,2010,33(25)：59-60.
[49]孟康,吕树铮,朱华刚等.血栓弹力图指导老年择期经皮冠状动脉介入患者抗血小板药物使用的研究[J].中国医药,2010,5(9)：782-784.
[50]王芳,迟云鹏.应用血栓弹力图指导PCI术后三联抗血小板药物方案实施的可行性分析[J].中国实用医药,2010,5(7)：17-19.
[51]Morton J, Nelluri S. Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance:a case report[J]. J Extra Corpor Technol,2009 Mar,41(1):32-36.
[52]Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance[J]. Hematology Am Soc Hematol Educ Program,2007,114-120.
[53]Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction[J]. Am J Cardiol,2005 Apr 15,5(8):973-975.
[54]MacDonald TM, Wei L. Effect of ibuprofen on cardionrotective effect of aspirin [J]. Lancet,2003 Feb 15,361(9357):573-574.
[55]Patrono C, Falco A, Davi G. Isoprostane formation and inhibition in atherothrombosis [J]. Curr Opin Pharmacol,2005 Apr,5 (2):198-203.
[56]Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin [J]. Clin Pharmacol Thcr,2003 Jan,73(1):122-130.
[57]O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation:the Framingham heart study [J]. Circulation, 2001 Jun 26,103(25):3051-3056.
[58]Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial [J]. Diabetes Care,2003 Dec, 26(12):3264-3272.
[59]Friend M, Vucenik I, Miller M BMJ. Research pointers:Platelet responsiveness to aspirin in patients with hyperlipidaemia [J]. BMJ,2003 Jan 11,326(7380):82-83.
[60]Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more aggressive dosing regimens in unstable angina?[J] Catheter Cardiovasc Interv,2003 May,59(1):21-25.
[61]Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel [J]. J Intern Med,2002 Sep, 252(3):233-238.
[62]Inzucchi SE. Type 2 diabetes mellitus and insulin resistance:stroke prevention and management [J]. Current Treatment Options in Neurology,2004,6(6):443-450.
[63]Westerbacka J, Yki-Jarvinen H. Arterial stiffness and insulin resistance. Semin Vase Med,2002 May,2(2):157-164.
[64]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J,2004 Mar,25(6):476-483.
[65]Savi P, Pereillo JM, Uzahiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel[J]. Thromb Haemost,2000 Nov, 84(5):891-896.
[66]Jvis Blair, Simpson Kerryn. Clopidogrel:a review of its use in the prevention of atherothrombosis[J]. Drugs,2000,60(2):347-377.
[67]Sibbing D, Morath T, Stegherr J,et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009 Apr,101(4):714-719.
[68]Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009 Mar 31, 180(7):713-718.
[69]Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation,2003 Jun 17,107(23):2908-2913.
[70]Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation, 2003,107(1):32-37.
[71]Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies[J]. Am J Cardiol,2003 Aug 1,92(3):285-288.
[72]吴桂萍,郑建勇,王芳等.氯吡格雷低反应性与急性冠状动脉综合征患者 再发缺血事件相关性研究[J].临床荟萃,2008,23(4)：238-240
[73]Matetzky S, Shenkman B, Guetta V,et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J]. Circulation,2004 Jun 29,109(25):3171-3175.
[74]Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome[J]. J Thromb Haemost,2006 Mar,4(3):542-549.
[75]Buonamici P, Marcucci R, Migliorini A, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis [J]. J Am Coll Cardiol, 2007 Jun 19,49(24):2312-2317.
[76]Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital [J]. Am J Cardi-ol,2006,98(5):577-579.
[77]Mosca L,Collins P,Herrington DM,et al.Hormone replacement therapy and cardiovascular Diserse:a statement for health Care professionals from the American Heart Association[J].Circulation,2001,104(11):499-503.
[78]Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel [J]. J Am Coll Cardiol,2008 Aug 12, 52(7):531-533.
[79]Jeong YH, Cho JH, Kang MK, et al. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction[J]. Thromb Res,2010 Oct,126(4):e334-338.
[80]Taniyama Y,Ito H,Morishita R,et al.Potential of microvascular reperfusion with adjunctive pharmacological intervention[J]. Drugs,2001,61(4):437-441.
[81]Ehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel [J]. Circulation,2004 Dec 14,110(24):3627-3635.
[82]Llaeys MJ, Van der Planken MG, Bosmans JM, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein Ⅱb/Ⅲa antagonists during elective coronary stenting? [J] A focus on peri-procedural myonecrosis. Eur Heart J,2005,26(6):567-575.
[1]Hartert H. Die Thrombelastographie, Eine Methode zur Physikalischen Analyse des Blutgernungsyorigangs[J]. Ztschr ges exper Med,1951,117:189-203.
[2]Harlert H. The Physical and Biological Constants of Thrombelastography[J]. Biorheology,1962,1:31-39.
[3]Craft RM, Chavez JJ, Snider CC, et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients [J]. J Lab Clin Med,2005 Jun,145(6):309-315.
[4]Miller BE, Tosone SR, Guzzetta NA, et al. Fibrinogen in children undergoing cardiac surgery:is it effective? [J] Anesth Analg,2004 Nov,99(5):1341-1346.
[5]R.J.Luddington. Thrombelastography/Thromboelastometry[J]. Clinical & Laboratory Haematology,2005,27(2):81-90.
[6]潘道波,黄平,朱明瑶.围手术期凝血功能障碍与TEG检测[J].医学临床研究,2004,21(9)：218-220.
[7]刘克立,黄文起,陈秉学,等.血栓弹性描记仪的临床应用初探[J].现代医学仪器与应用,2000,12(3)：11-13.
[8]李丹丹,任艺虹,杨庭树.改良血栓弹力图及其在辅助冠心病诊疗方面的研究进展[J].西南国防医药,2008,18(2)：301-302.
[9]许峰,孟康,吕树铮.血栓弹力图在冠心病介入治疗患者抗栓监测中的应用[J].中国医药,2010,5(9)：777-778.
[10]徐晓薇,杜凤和.根据血栓弹力图结果指导急性冠脉综合征患者抗血小板药物的使用[J].中国医师进修杂志,2010,33(25)：59-60
[11]Morange PE, Blankenberg S, Alessi MC, et al. Prognostic Value of Plasma tissue Factor and Tissue Factor Pathway Inhibitor for Cardiovascular Death in Patients with Coronary Artery Disease:the Athero Gene study[J]. J Thromb Haemost,2007,5:475-482.
[12]李巧汶,邱健,马骏,等.冠心病患者凝血机制的变化及其临床意义[J].中华老年心脑血管病杂志,2008,10(4)：257-259.
[13]Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute
ischemic syndromes[J]. Circulation,1988,77:1213-1220.
[14]胡豫,等.陈旧性心肌梗塞患者凝血纤溶状态的研究[J].同济医科大学学报,1998,27(4)：277-279.
[15]张红雨,宋善俊,涂源淑.冠心病患者血浆纤维蛋白肽A及有关参数的研究[J].临床心血管杂志,1999,15(5)：197-199.
[16]柯元南.动脉粥样硬化的抗栓和抗凝治疗[J].中国循环杂志,2007,22(6)：476-478.
[17]陈国伟.抗血小板及抗凝治疗的最新进展[J].中国使用内科杂志,2003,23(8)：457-458
[18]Young G。Yonekawa K E, NakaGAm P A, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastngraphy[J]. Blood Coagul Fibrinolysis,2007,18 (6):547-553.
[19]陆志强,陈宇,粱永年,等.盐酸替罗非班修饰的血栓弹力图与血纤维蛋白原浓度的相关性[J].临床麻醉学杂志,2007,23(5)：376—378.
[20]林艺虹,盖鲁粤,杨庭树,等.改良血栓弹力图法和流式细胞测定技术对血小板活性抑制程度的比较[J].中华心血管病杂志,2007,35(4)：366—367.
[21]Kouerinis IA, El-Ali M, Theakos N. Can thromboelastography predict which patients with heparin-induced thrombocytopenia may suffer thrombotic complications of type Ⅱ[J]? Eur J Cardiothorac Surg,2007 Sep,32(3):544-546.
[22]Kouerinis IA, Kourtesis A, El-Ali M. Heparin induced thrombocytopenia diagnosis in cardiac surgery:is there a role for thromboelastography[J]? Interact Cardiovasc Thorac Surg,2008 Aug,7(4):560-563
[23]Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI—CURE study[J]. Lancet,2001,385(9281):527 —533.
[24]Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelel therapy following percutancous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[25]薛朝阳,陈媛,陆民.冠状动脉介入术对血小板活性的影响及与支架血栓的关系[J].中国介入心脏病学杂志,2009,17(6)：320-323.
[26]Wenaweser P, Dorffler MJ, lmboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy [J]. J Am Coil Cardiol,2005,45: 1748-1752.
[27]Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post--clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation[J]. Eur Heart J,2008,29(8):992-1000.
[28]Lev El, Patel RT, Maresh KJ. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance[J]. J Am Coll Cardiol,2006,47:27-33.
[29]Malek tA. Spiewak M, Filipiak KJ, et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes[J]. KardiolP01,2007-65(1):40-45.
[30]Dichiara J, Bliden K P, Tantry U S, et al. Platelet Function Measured by VerifyNowtrade Mark Identifies Generalized High Platelet Reactivity in Aspirin Treated patients[J]. Platelets,2007,18(6):414—423.
[31]Gurbel PA, Bliden K.P, Guyer K, et al. Platelet reactivity in patients and recurrent events post—stenting:results of the PREPAREPOST—STENTING Study[J]. J Am Coil Cardiol,2005,46(10):1820-1826.
[32]布伦,唐发宽,齐帜,等.经皮冠状动脉介入术后患者血小板抑制率的血栓弹力图测定[J].中国康复理论与实践,2010,16(5)：417-418.
[33]Hobson AR, Agarwala RA, Swallow RA, et al. Thrombelnstography:current clinical applications and its potential role in intervention cardiology[J]. Platelets, 2006,17(8):509-518.
[34]Lev El, Patel RT, Maresh KJ. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance[J]. J Am Coll Cardiol,2006,47:27-33.
[35]Bliden KP, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate[J]? J Am Coll Cardiol,2007,3,49(6): 657-666.
[36]Hobson AR, Agarwala RA, Swallow RA, et al. Thrombelnstography:current clinical applications and its potential role in intervention cardiology[J]. Platelets, 2006,17(8):509-518.
[37]Papa ML, Capasso F, Pudore L, et al. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer [J]. Exp Oncol,2007,29(2):111-155.
[2]Bakhtiari K, C.M. Meijers J, de Jonge E, etc. Prospective validation of the International Society of Thrombosis and Haemostasis Scoring system for disseminated intravascular coagulation [J]. Crit Care Med,2004,32:2416-2421.
[3]Hartert H. Thrombelastography, a method for physical analysis of blood coagulation [J]. Z Gesamte Exp Med,1951,117(2):189-203.
[4]Craft RM, Chavez JJ, Snider CC, et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients [J]. J Lab Clin Med,2005 Jun,145(6):309-315.
[5]Miller BE, Tosonc SR, Guzzctta NA, et al. Fibrinogen in children undergoing cardiac surgery:is it effective? [J] Anesth Analg,2004 Nov,99(5):1341-1346.
[6]Salooja N, Perry DJ. Thrombelastography [J]. Blood Coagul Fibrinolysis,2001 Jul, 12(5):327-337.
[7]Wheeler AP, Bernard GR. Treating patients with severe sepsis [J]. N Engl J,Med, 1999,340:207-214.
[8]叶任高,陆再英.内科学[M].第6版.北京：人民卫生出版社,2004,
[9]周北凡,吴锡桂,主编.心血管病学流行病学调查手册[M].北京：北京医科大学中国协和医科大学联合出版社,1997,69-75.
[10]Harlan M, Krumholz MD, Jeffrey L. Anderson MD, et al. ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction [J]. Circulation,2008 Nov,118(24):2596-2648.
[11]Jeffrey L. Anderson, MD, Cynthia D. Adams, RN, Elliott M. Antman, MD, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [J]. Circulation,2011 Mar,123:e426-e579.
[12]Theodore D, Fraker, MD, Stephan, MD, et al.2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina[J]. Circulation,2007 Nov,116(23):2762-2772.
[13]中国高血压防治指南修订委员会.2004年中国高血压防治指南[J].中华心血管病杂志,2004,32(12)：1060-1064.
[14]叶任高,陆再英.内科学[M].第6版.北京：人民卫生出版社,2004,787-814.
[15]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5)：390-413.
[16]Frederick G. Kushner MD, Mary Hand MSPH. Sidney C. Smith Jr MD,et al. 2009 Focused Updates:ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention[J]. Circulation,2009 Dec,120(22):2271-2306
[17]Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation [J]. J Am Coll Cardiol,2005, 46(9):1705-1709.
[18]Pieper CF, Rao KM, Currie MS, et al. Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons [J]. Gerontol A Biol Sci Med Sci,2000 Nov,55(11):M649-657.
[19]李晓春,刘东岳.D-二聚体测定在心血管疾病中的临床应用价值[J].国外医学.心血管疾病分册,1997,24(5)：26.
[20]张广森,王鸿利.血栓形成机制,见：李家增,贺石林,王鸿利,等主编.血栓病学[M].北京科学出版社,1998：13-14.
[21]胡豫等.陈旧性心肌梗塞患者凝血纤溶状态的研究[J].同济医科大学学报,1998,27(4)：277-279.
[22]张红雨,宋善俊,涂源淑.冠心病患者血浆纤维蛋白肽A及有关参数的研究[J].临床心血管杂志,1999,15(5)：197-199.
[23]Schlant RC, Forman S, Stajnler J, et al. The natural history of coronary heart disease:prognostic factors after recovery from myocardial infarction in 2789 men. The 5 year findings of the coronary drug project [J].Circulation,1982,66:411-414.
[24]Barron HV, Cannon CP, MurPhy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction:a thrombolysis in myocardial infarction 10 substudy [J].Circulation,2000,102:2329-2334.
[25]Gurm HS, Bhatt DL, Lincoff AM, et al. Impact of preprocedural white. Blood cell count on long term mortality after percutaneous coronary intervention:insights from the EPIC, EPILOG, and EPISTENT trials[J]. Heart,2003,89(10):1200-1204.
[26]Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 investigators [J]. Am J Cardiol,2001,87:636-639.
[27]Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease [J]. Ann Intern Med,1951 Jun, 34(6):1421-1431.
[28]Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I Epidemiologic Follow-up Study,1971-1992 [J]. National Health and Nutrition Examination Survey [J]. JAMA,2000 May 10,283(18):2404-2410.
[29]Alderman MH. Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients[J]. Hypertension,1999 Jul,34(1):144-150.
[30]Nieto FJ, Iribarren C, Gross MD, et al. Uric acid and serum antioxidant capacity:a reaction to atherosclerosis[J]? Atherosclerosis,2000 Jan,148(1):131-139.
[31]Cianflone D, Ciccirillo F, Buffon A, et al. Comparison of coronary angiograpbic narrowing in stable angina pectoris, unstable angina pectoris and in acute myocardial infarction [J]. Am J cordial,1995 Aug 1,76(4):215-219.
[32]Bogaty P, Brecker SJ, White SE, et al. Comparison of coronary angiographic findings in acute and chronic first presentation of ischemic heart disease[J]. Circulation,1993 Jun,87(6):1938-1946.
[33]郑鹏翔,华尔铨,张书富等.稳定性心绞痛,不稳定型心绞痛,急性心肌梗死的冠脉造影特点[J].中国医药指南,2005,3(5)：90-492.
[34]De Feyter PJ, Ozaki Y, Baptista J, et al. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound[J]. Circulation,1995 Sep 15,92(6):1408-1413.
[35]戴军,高润霖,陈纪林等.35岁以下与45岁以上心肌梗塞患者临床特征比较[J].中华内科杂志,1999,38(2)：104-106.
[36]Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly[J]. N Engl J Med,1997 May 1,36(18):1276-1282.
[37]Krasopoulos G, Brister SJ, Beattie WS,et al. Aspirin "resistance" and risk of cardiovascular morbidity:systematic review and meta-analysis[J]. BMJ,2008 Jan 26, 336(7637):195-198.
[38]Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance:position paper of the Working Group on Aspirin Resistance [J]. J Thromb Haemost,2005 Jun, 3(6):1309-1311.
[39]Patrono C. Aspirin resistance:definition, mechanisms and clinical read-outs[J]. J Thromb Haemost,2003 Aug,1(8):1710-1713.
[40]Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting:results of the PREPARE POST-STENTING Study[J]. J Am Coll Cardiol,2005 Nov 15,6(10):1820-1826.
[41]Sztriha L, Sas K, Vecsei L. Aspirin resistance in stroke:2004[J]. J neurol sci,2005 Mar 15,229-230:163-169.
[42]Wiviott SD, Antman EM. Clopidogrel resistance:a new chapter in a fast-moving story [J].Circulation,2004 Jun 29,109(25):3064-3067.
[43]Patrono C, Baigent C, Hirsh J. Roth G. Antiplatelet drugs:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [J]. Chest,2008 Jun,33(6 Suppl):199S-233S.
[44]Hennekens CH, Schror K, Weisman S, et al. Terms and conditions:semantic complexity and aspirin resistance [J]. Circulation,2004 Sep 21,10(12):1706-1708.
[45]Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance [J]. J Am Coll Cardiol,2006 Jan 3,47(1):27-33.
[46]FitzGerald GA. Parsing an enigma:the pharmacodynamics of aspirin resistance[J]. Lancet,2003 Feb 15,361(9357):542-544.
[47]Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital[J]. Am J Cardiol,2006 Sep 1,98(5):577-579.
[48]徐晓微,杜凤和.根据血栓弹力图结果指导急性冠脉综合征患者抗血小板药 物的使用[J].中国医师进修杂志,2010,33(25)：59-60.
[49]孟康,吕树铮,朱华刚等.血栓弹力图指导老年择期经皮冠状动脉介入患者抗血小板药物使用的研究[J].中国医药,2010,5(9)：782-784.
[50]王芳,迟云鹏.应用血栓弹力图指导PCI术后三联抗血小板药物方案实施的可行性分析[J].中国实用医药,2010,5(7)：17-19.
[51]Morton J, Nelluri S. Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance:a case report[J]. J Extra Corpor Technol,2009 Mar,41(1):32-36.
[52]Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance[J]. Hematology Am Soc Hematol Educ Program,2007,114-120.
[53]Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction[J]. Am J Cardiol,2005 Apr 15,5(8):973-975.
[54]MacDonald TM, Wei L. Effect of ibuprofen on cardionrotective effect of aspirin [J]. Lancet,2003 Feb 15,361(9357):573-574.
[55]Patrono C, Falco A, Davi G. Isoprostane formation and inhibition in atherothrombosis [J]. Curr Opin Pharmacol,2005 Apr,5 (2):198-203.
[56]Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin [J]. Clin Pharmacol Thcr,2003 Jan,73(1):122-130.
[57]O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation:the Framingham heart study [J]. Circulation, 2001 Jun 26,103(25):3051-3056.
[58]Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial [J]. Diabetes Care,2003 Dec, 26(12):3264-3272.
[59]Friend M, Vucenik I, Miller M BMJ. Research pointers:Platelet responsiveness to aspirin in patients with hyperlipidaemia [J]. BMJ,2003 Jan 11,326(7380):82-83.
[60]Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention:do we need more aggressive dosing regimens in unstable angina?[J] Catheter Cardiovasc Interv,2003 May,59(1):21-25.
[61]Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel [J]. J Intern Med,2002 Sep, 252(3):233-238.
[62]Inzucchi SE. Type 2 diabetes mellitus and insulin resistance:stroke prevention and management [J]. Current Treatment Options in Neurology,2004,6(6):443-450.
[63]Westerbacka J, Yki-Jarvinen H. Arterial stiffness and insulin resistance. Semin Vase Med,2002 May,2(2):157-164.
[64]Lepantalo A, Virtanen KS, Heikkila J, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J,2004 Mar,25(6):476-483.
[65]Savi P, Pereillo JM, Uzahiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel[J]. Thromb Haemost,2000 Nov, 84(5):891-896.
[66]Jvis Blair, Simpson Kerryn. Clopidogrel:a review of its use in the prevention of atherothrombosis[J]. Drugs,2000,60(2):347-377.
[67]Sibbing D, Morath T, Stegherr J,et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009 Apr,101(4):714-719.
[68]Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel[J]. CMAJ,2009 Mar 31, 180(7):713-718.
[69]Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting:response variability, drug resistance, and the effect of pretreatment platelet reactivity[J]. Circulation,2003 Jun 17,107(23):2908-2913.
[70]Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation:a new drug-drug interaction[J]. Circulation, 2003,107(1):32-37.
[71]Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies[J]. Am J Cardiol,2003 Aug 1,92(3):285-288.
[72]吴桂萍,郑建勇,王芳等.氯吡格雷低反应性与急性冠状动脉综合征患者 再发缺血事件相关性研究[J].临床荟萃,2008,23(4)：238-240
[73]Matetzky S, Shenkman B, Guetta V,et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J]. Circulation,2004 Jun 29,109(25):3171-3175.
[74]Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome[J]. J Thromb Haemost,2006 Mar,4(3):542-549.
[75]Buonamici P, Marcucci R, Migliorini A, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis [J]. J Am Coll Cardiol, 2007 Jun 19,49(24):2312-2317.
[76]Mirkhel A, Peyster E, Sundeen J, et al. Frequency of aspirin resistance in a community hospital [J]. Am J Cardi-ol,2006,98(5):577-579.
[77]Mosca L,Collins P,Herrington DM,et al.Hormone replacement therapy and cardiovascular Diserse:a statement for health Care professionals from the American Heart Association[J].Circulation,2001,104(11):499-503.
[78]Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel [J]. J Am Coll Cardiol,2008 Aug 12, 52(7):531-533.
[79]Jeong YH, Cho JH, Kang MK, et al. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction[J]. Thromb Res,2010 Oct,126(4):e334-338.
[80]Taniyama Y,Ito H,Morishita R,et al.Potential of microvascular reperfusion with adjunctive pharmacological intervention[J]. Drugs,2001,61(4):437-441.
[81]Ehilli J, Kastrati A, Schuhlen H, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel [J]. Circulation,2004 Dec 14,110(24):3627-3635.
[82]Llaeys MJ, Van der Planken MG, Bosmans JM, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein Ⅱb/Ⅲa antagonists during elective coronary stenting? [J] A focus on peri-procedural myonecrosis. Eur Heart J,2005,26(6):567-575.
[1]Hartert H. Die Thrombelastographie, Eine Methode zur Physikalischen Analyse des Blutgernungsyorigangs[J]. Ztschr ges exper Med,1951,117:189-203.
[2]Harlert H. The Physical and Biological Constants of Thrombelastography[J]. Biorheology,1962,1:31-39.
[3]Craft RM, Chavez JJ, Snider CC, et al. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients [J]. J Lab Clin Med,2005 Jun,145(6):309-315.
[4]Miller BE, Tosone SR, Guzzetta NA, et al. Fibrinogen in children undergoing cardiac surgery:is it effective? [J] Anesth Analg,2004 Nov,99(5):1341-1346.
[5]R.J.Luddington. Thrombelastography/Thromboelastometry[J]. Clinical & Laboratory Haematology,2005,27(2):81-90.
[6]潘道波,黄平,朱明瑶.围手术期凝血功能障碍与TEG检测[J].医学临床研究,2004,21(9)：218-220.
[7]刘克立,黄文起,陈秉学,等.血栓弹性描记仪的临床应用初探[J].现代医学仪器与应用,2000,12(3)：11-13.
[8]李丹丹,任艺虹,杨庭树.改良血栓弹力图及其在辅助冠心病诊疗方面的研究进展[J].西南国防医药,2008,18(2)：301-302.
[9]许峰,孟康,吕树铮.血栓弹力图在冠心病介入治疗患者抗栓监测中的应用[J].中国医药,2010,5(9)：777-778.
[10]徐晓薇,杜凤和.根据血栓弹力图结果指导急性冠脉综合征患者抗血小板药物的使用[J].中国医师进修杂志,2010,33(25)：59-60
[11]Morange PE, Blankenberg S, Alessi MC, et al. Prognostic Value of Plasma tissue Factor and Tissue Factor Pathway Inhibitor for Cardiovascular Death in Patients with Coronary Artery Disease:the Athero Gene study[J]. J Thromb Haemost,2007,5:475-482.
[12]李巧汶,邱健,马骏,等.冠心病患者凝血机制的变化及其临床意义[J].中华老年心脑血管病杂志,2008,10(4)：257-259.
[13]Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute
ischemic syndromes[J]. Circulation,1988,77:1213-1220.
[14]胡豫,等.陈旧性心肌梗塞患者凝血纤溶状态的研究[J].同济医科大学学报,1998,27(4)：277-279.
[15]张红雨,宋善俊,涂源淑.冠心病患者血浆纤维蛋白肽A及有关参数的研究[J].临床心血管杂志,1999,15(5)：197-199.
[16]柯元南.动脉粥样硬化的抗栓和抗凝治疗[J].中国循环杂志,2007,22(6)：476-478.
[17]陈国伟.抗血小板及抗凝治疗的最新进展[J].中国使用内科杂志,2003,23(8)：457-458
[18]Young G。Yonekawa K E, NakaGAm P A, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastngraphy[J]. Blood Coagul Fibrinolysis,2007,18 (6):547-553.
[19]陆志强,陈宇,粱永年,等.盐酸替罗非班修饰的血栓弹力图与血纤维蛋白原浓度的相关性[J].临床麻醉学杂志,2007,23(5)：376—378.
[20]林艺虹,盖鲁粤,杨庭树,等.改良血栓弹力图法和流式细胞测定技术对血小板活性抑制程度的比较[J].中华心血管病杂志,2007,35(4)：366—367.
[21]Kouerinis IA, El-Ali M, Theakos N. Can thromboelastography predict which patients with heparin-induced thrombocytopenia may suffer thrombotic complications of type Ⅱ[J]? Eur J Cardiothorac Surg,2007 Sep,32(3):544-546.
[22]Kouerinis IA, Kourtesis A, El-Ali M. Heparin induced thrombocytopenia diagnosis in cardiac surgery:is there a role for thromboelastography[J]? Interact Cardiovasc Thorac Surg,2008 Aug,7(4):560-563
[23]Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI—CURE study[J]. Lancet,2001,385(9281):527 —533.
[24]Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelel therapy following percutancous coronary intervention:a randomized controlled trial[J]. JAMA,2002,288(19):2411-2420.
[25]薛朝阳,陈媛,陆民.冠状动脉介入术对血小板活性的影响及与支架血栓的关系[J].中国介入心脏病学杂志,2009,17(6)：320-323.
[26]Wenaweser P, Dorffler MJ, lmboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy [J]. J Am Coil Cardiol,2005,45: 1748-1752.
[27]Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post--clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation[J]. Eur Heart J,2008,29(8):992-1000.
[28]Lev El, Patel RT, Maresh KJ. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance[J]. J Am Coll Cardiol,2006,47:27-33.
[29]Malek tA. Spiewak M, Filipiak KJ, et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes[J]. KardiolP01,2007-65(1):40-45.
[30]Dichiara J, Bliden K P, Tantry U S, et al. Platelet Function Measured by VerifyNowtrade Mark Identifies Generalized High Platelet Reactivity in Aspirin Treated patients[J]. Platelets,2007,18(6):414—423.
[31]Gurbel PA, Bliden K.P, Guyer K, et al. Platelet reactivity in patients and recurrent events post—stenting:results of the PREPAREPOST—STENTING Study[J]. J Am Coil Cardiol,2005,46(10):1820-1826.
[32]布伦,唐发宽,齐帜,等.经皮冠状动脉介入术后患者血小板抑制率的血栓弹力图测定[J].中国康复理论与实践,2010,16(5)：417-418.
[33]Hobson AR, Agarwala RA, Swallow RA, et al. Thrombelnstography:current clinical applications and its potential role in intervention cardiology[J]. Platelets, 2006,17(8):509-518.
[34]Lev El, Patel RT, Maresh KJ. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance[J]. J Am Coll Cardiol,2006,47:27-33.
[35]Bliden KP, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate[J]? J Am Coll Cardiol,2007,3,49(6): 657-666.
[36]Hobson AR, Agarwala RA, Swallow RA, et al. Thrombelnstography:current clinical applications and its potential role in intervention cardiology[J]. Platelets, 2006,17(8):509-518.
[37]Papa ML, Capasso F, Pudore L, et al. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer [J]. Exp Oncol,2007,29(2):111-155.